Truist analyst Joon Lee lowered the firm’s price target on Viking Therapeutics (VKTX) to $75 from $95 but keeps a Buy rating on the shares. 2025 will be a year of execution as Viking embarks on Phase 3 program in obesity, though given intensifying competition in the obesity space, the firm is moderating its estimates, the analyst tells investors in a research note. Truist adds however that even a modest penetration into obesity, the largest therapeutic category, should be material for Viking.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics participates in a conference call with Maxim Group
- Promising Developments and Strong Financial Position Bolster Buy Rating for Viking Therapeutics
- Viking Therapeutics: Promising Pipeline and Strategic Execution Drive Buy Rating
- Viking Therapeutics price target lowered to $85 from $96 at B. Riley
- Viking Therapeutics: Strong Financials and Promising VK2735 Program Drive Buy Rating